Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus BETAXON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus BETAXON.
BETAGAN vs BETAXON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Category C
Category C
Beta-Blocker
Beta-Blocker